本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600829 证券简称：人民同泰 公告编号：临 2025-023 哈药集团人民同泰医药股份有限公司 关于开展 2025 年应收账款无追索权保理业务的公告 公司拟开展不超过人民币2.80亿元无追索权应收账款保理业务。 本次开展应收账款无追索权保理业务相关议案已经公司审计委员会2025年第七次 会议、第十一届董事会第二次会议审议通过。 本次交易不构成关联交易、不构成重大资产重组。 一、 应收账款保理业务情况概述 为加速资金周转，提高资金使用效率，降低应收账款风险，哈药 集团人民同泰医药股份有限公司（以下简称"公司"）拟与国内商业 银行开展应收账款保理业务。 根据《上海证券交易所股票上市规则》《上市公司自律监管指引 第一号——规范运作》及《公司章程》的相关规定，本次保理业务不 构成关联交易，也不构成《上市公司重大资产重组管理办法》规定的 重大资产重组。本次开展保理业务无需提交股东会审议。 二、 应收账款保理业务的基本情况 1.保理标的：公司及合并报表范围内分子 ...

证券代码:600829 证券简称:人民同泰 公告编号:临 2025-022 哈药集团人民同泰医药股份有限公司 第十一届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 哈药集团人民同泰医药股份有限公司（以下简称"公司"）第十一 届董事会第二次会议通知于2025年7月28日以书面及电子邮件方式向 全体董事发出，会议于 2025 年 8 月 8 日在公司七楼会议室以现场结合 通讯方式召开。本次会议应出席董事 7 人，实际出席董事 7 人，会议由 董事长朱卫东先生主持，公司高级管理人员列席本次会议。本次会议的 召集、召开和表决程序符合《公司法》《公司章程》《董事会议事规则》 的规定。 二、董事会会议审议情况 经全体董事认真审议，本次会议以记名投票表决方式表决通过了如 下议案： （一）审议通过《2025 年半年度报告》及摘要 本议案已经公司董事会审计委员会2025年第七次会议审议通过。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn） 及指定媒体披露的《2025 年半年度报告》及其摘要。 ...

公司代码：600829 公司简称：人民同泰 哈药集团人民同泰医药股份有限公司 2025 年半年度报告 哈药集团人民同泰医药股份有限公司2025 年半年度报告 二〇二五年八月 1 / 133 哈药集团人民同泰医药股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人朱卫东、主管会计工作负责人管平及会计机构负责人（会计主管人员）张鉴声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 本报告中所涉及的经营计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，敬 请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风 ...

格隆汇8月8日丨人民同泰(600829.SH)公布半年度报告，报告期内，公司实现营业收入514,933.09万元， 较上年同期增长3.29%；实现归属于上市公司股东的净利润7,257.92万元，较上年同期下降46.31%；毛 利率8.04%，较上年同期下降1.04%。直营门店376家；会员人数270余万人。 ...

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the 31 listed pharmaceutical companies, 28 have active secretaries, with the age distribution showing that 57% are between 40-50 years old, 11% are over 50, and 32% are 40 or younger [1] - The educational background of secretaries indicates that 50% hold a bachelor's degree, 46% have a master's degree, and only 4% possess a doctoral degree, with only one secretary having a PhD [1] Group 2 - The average annual salary of secretaries in A-share pharmaceutical companies is 726,500 yuan, with 43% earning below 500,000 yuan, 36% between 500,000-1 million yuan, 18% between 1-2 million yuan, and 3% above 2 million yuan [2] - The top three highest-paid secretaries are from Shanghai Pharmaceuticals, Run Da Medical, and China National Pharmaceutical Group, with salaries of 2.0373 million yuan, 1.6242 million yuan, and 1.2 million yuan respectively [2] - The largest salary decrease was observed for Wang Lei from Renmin Tongtai, with a year-on-year decline of 60.61%, while Zhang Yufeng from Zhejiang Zhenyuan experienced the largest increase at 212.33% [2]

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the 31 listed pharmaceutical companies, 28 have active secretaries, with the age distribution showing that 57% are between 40-50 years old, 11% are over 50, and 32% are 40 or younger [1] - The educational background of secretaries indicates that 50% hold a bachelor's degree, 46% have a master's degree, and only 4% possess a doctoral degree, with only one secretary holding a PhD [1] Group 2 - The average annual salary of secretaries in A-share pharmaceutical companies is 726,500 yuan, with 43% earning below 500,000 yuan, 36% between 500,000-1 million yuan, 18% between 1 million-2 million yuan, and 3% earning over 2 million yuan [2] - The top three highest-paid secretaries are Zhong Tao from Shanghai Pharmaceuticals with 2.0373 million yuan, Zhang Chengxu from Run Da Medical with 1.6242 million yuan, and Luo Lichun from China National Pharmaceutical with 1.2 million yuan [2] - The largest salary decrease was observed for Wang Lei from Renmin Tongtai, with a year-on-year decline of 60.61%, while Zhang Yufeng from Zhejiang Zhenyuan experienced the largest increase at 212.33% [2]

Group 1 - The total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Among the 31 listed pharmaceutical companies, 28 have active secretaries, with the age distribution showing that 57% are between 40-50 years old, 11% are over 50, and 32% are 40 or younger [1] - The educational background of secretaries indicates that 50% hold a bachelor's degree, 46% have a master's degree, and only 4% possess a doctoral degree, with only one secretary having a PhD [1] Group 2 - The average annual salary of secretaries in A-share pharmaceutical companies is 726,500 yuan, with 43% earning below 500,000 yuan, 36% between 500,000-1 million yuan, 18% between 1 million-2 million yuan, and 3% earning over 2 million yuan [2] - The top three highest-paid secretaries are Zhong Tao from Shanghai Pharmaceuticals with 2.0373 million yuan, Zhang Chengxu from Run Da Medical with 1.6242 million yuan, and Luo Lichun from China National Pharmaceutical with 1.2 million yuan [2] - The largest salary decrease was observed for Wang Lei from Renmin Tongtai, with a year-on-year decline of 60.61%, while Zhang Yufeng from Zhejiang Zhenyuan experienced the largest increase at 212.33% [2]

证券之星消息，7月31日医药商业板块较上一交易日下跌1.61%，人民同泰领跌。当日上证指数报收于 3573.21，下跌1.18%。深证成指报收于11009.77，下跌1.73%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 301126 | 达嘉维康 | 12.52 | 3.81% | | 33.74万 | 4.37 乙 | | 301015 | 百洋医药 | 22.07 | 0.68% | | 12.32万 | 2.71亿 | | 603108 | 润达医疗 | 18.31 | 0.60% | | 34.20万 | 6.33亿 | | 002589 | 瑞康医药 | 3.13 | 0.00% | | 37.63万 | 1.18亿 | | 300937 | 药易购 | 30.41 | -0.13% | | 5.74万 | 1.77亿 | | 301017 | 激干平民 | 13.08 | -0.38% | | 7.56万 | 9956.06万 | ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603716 | 塞力医疗 | 31.62 | -4.62% | 53.88万 | 17.35 Z | | 002727 | 一心室 | 15.16 | -1.62% | 24.81万 | 3.74亿 | | 301408 | 华人健康 | 14.23 | -1.52% | 12.38万 | 1.76亿 | | 301126 | 达嘉维康 | 11.81 | -1.34% | 12.83万 | 1.54亿 | | 600713 | 南京医药 | 5.30 | -0.38% | 10.15万 | 5359.40万 | | 603939 | 益丰药房 | 23.85 | -0.29% | 13.61万 | 3.24亿 | | 600511 | 国药股份 | 29.85 | -0.23% | 3.59万 | 1.07亿 | | 605266 | 健之佳 | 21.93 | -0.09% | 2.33万 | 5098.20万 | | 002589 | 瑞康 ...

New Stock Issuance - New stock issued by Dingjia Precision at a price of 11.16 on July 22, 2025[1] - ST Kelly's tender offer period is from July 17 to August 15, 2025[1] - ST Zitian and other companies have also announced new stock issuances[1] Market Alerts - Significant abnormal fluctuations reported for several stocks including Guangshengtang and Huayin Power[1] - Multiple companies have disclosed announcements regarding stock performance and market activities[1] - The report includes links to detailed announcements for various stocks, indicating ongoing market monitoring[1]